Liquidia Corp (LQDA)

$56.60 +3.47 (6.53%)
Market Cap 4.72B
Revenue (ttm) 158.32M
Net Income (ttm) -68.92M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 24.17
Profit Margin -43.53%
Debt to Equity Ratio 4.28
Volume 3,928,600
Avg Vol 1,346,262
Day's Range N/A - N/A
Shares Out 88.89M
Stochastic %K 98%
Beta 0.41
Analysts Strong Sell
Price Target $54.62

Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intr...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 328 4400
Fax: 919 328 4402
Address:
419 Davis Drive, Suite 100, Morrisville, United States
KeelinTime
KeelinTime May. 13 at 10:40 AM
$LQDA
0 · Reply
BDE_Worldwide
BDE_Worldwide May. 13 at 3:58 AM
$LQDA lol, been battlin’ shorts since 2021.. Know what you own. Buyout in 2026. Signed, sealed and delivered. 💎 🖐️
0 · Reply
BullRun4
BullRun4 May. 13 at 1:17 AM
$LQDA 👏🏻👏🏻👏🏻👏🏻⤵️⤵️⤵️⤵️😜😎💰
0 · Reply
KeelinTime
KeelinTime May. 13 at 12:33 AM
$LQDA
0 · Reply
JFais
JFais May. 12 at 10:45 PM
$LQDA (L) From today's trades
0 · Reply
IFeelLucky812
IFeelLucky812 May. 12 at 10:12 PM
$LQDA this story ends in an M&A story. I’ve been saying it for 5 years. PBM knows what they own and want top dollar. I wish I never trimmed my position, but still happy with what I hold from the $3 range. I remember fighting all the MNKD holders, I wonder what they are thinking!
0 · Reply
stevemano
stevemano May. 12 at 9:22 PM
$LQDA ridiculously overpriced!
1 · Reply
stevemano
stevemano May. 12 at 9:19 PM
$LQDA overvalued. Pump. N dump
0 · Reply
Quantumup
Quantumup May. 12 at 8:54 PM
BofA last night⬆️ $LQDA's PT to $64 (was $44), plus⬆️Yutrepia's peak sales estimates +40% to $1.7B while reiterating at Buy in its 1Q26 EPS wrap. $UTHR - MKND $INSM Here's what BofA had to say in its note to investors: https://x.com/Quantumup1/status/2054303381431505331?s=20
0 · Reply
truehealthvalue
truehealthvalue May. 12 at 7:56 PM
$LQDA @stevemano are you still live?
1 · Reply
Latest News on LQDA
Liquidia price target raised to $67 from $55 at H.C. Wainwright

2026-05-12T18:47:33.000Z - 16 hours ago

Liquidia price target raised to $67 from $55 at H.C. Wainwright

Liquidia price target raised to $62 from $51 at Wells Fargo

2026-05-12T11:38:21.000Z - 23 hours ago

Liquidia price target raised to $62 from $51 at Wells Fargo

Liquidia price target raised to $60 from $57 at Jefferies

2026-05-11T21:57:52.000Z - 1 day ago

Liquidia price target raised to $60 from $57 at Jefferies

Liquidia Earnings Call Transcript: Q1 2026

May 11, 2026, 8:30 AM EDT - 1 day ago

Liquidia Earnings Call Transcript: Q1 2026

Liquidia reports Q1 EPS 52c, consensus 41c

2026-05-11T11:28:55.000Z - 1 day ago

Liquidia reports Q1 EPS 52c, consensus 41c

Liquidia Corporation Reports First Quarter 2026 Financial Results

May 11, 2026, 6:30 AM EDT - 2 days ago

Liquidia Corporation Reports First Quarter 2026 Financial Results

Liquidia Corporation to Participate in Upcoming Investor Conferences

May 6, 2026, 8:30 AM EDT - 6 days ago

Liquidia Corporation to Participate in Upcoming Investor Conferences

Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

May 4, 2026, 8:30 AM EDT - 8 days ago

Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026

Liquidia Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 15, 2026, 12:45 PM EDT - 27 days ago

Liquidia Transcript: 25th Annual Needham Virtual Healthcare Conference

Liquidia price target raised to $51 from $44 at Wells Fargo

2026-03-23T10:32:21.000Z - 7 weeks ago

Liquidia price target raised to $51 from $44 at Wells Fargo

INSM

Liquidia Technologies put volume heavy and directionally bearish

2026-03-16T14:55:09.000Z - 2 months ago

Liquidia Technologies put volume heavy and directionally bearish

Liquidia price target raised to $19 from $16 at Oppenheimer

2026-03-12T11:52:04.000Z - 2 months ago

Liquidia price target raised to $19 from $16 at Oppenheimer

Liquidia rises 7.7%

2026-03-06T15:06:42.000Z - 2 months ago

Liquidia rises 7.7%

Liquidia price target raised to $55 from $50 at H.C. Wainwright

2026-03-06T11:16:01.000Z - 2 months ago

Liquidia price target raised to $55 from $50 at H.C. Wainwright

Liquidia files automatic mixed securities shelf

2026-03-05T21:46:18.000Z - 2 months ago

Liquidia files automatic mixed securities shelf

Liquidia Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 2 months ago

Liquidia Earnings Call Transcript: Q4 2025

Liquidia reports Q4 EPS 15c, consensus 33c

2026-03-05T11:37:50.000Z - 2 months ago

Liquidia reports Q4 EPS 15c, consensus 33c

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 5, 2026, 6:30 AM EST - 2 months ago

Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

Feb 26, 2026, 7:00 AM EST - 2 months ago

Liquidia Corporation to Report Full Year 2025 Financial Results on March 5, 2026

Liquidia reaction on United Therapeutics’ TreSMI reveal ‘overdone,’ says Needham

2026-02-25T17:50:33.000Z - 2 months ago

Liquidia reaction on United Therapeutics’ TreSMI reveal ‘overdone,’ says Needham

UTHR

Liquidia Technologies call volume above normal and directionally bullish

2026-01-16T18:05:12.000Z - 4 months ago

Liquidia Technologies call volume above normal and directionally bullish

Liquidia Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 8:15 PM EST - 4 months ago

Liquidia Transcript: 44th Annual J.P. Morgan Healthcare Conference

Liquidia price target raised to $55 from $45 at Jefferies

2026-01-13T16:05:24.000Z - 4 months ago

Liquidia price target raised to $55 from $45 at Jefferies

Liquidia rises 18.2%

2026-01-09T17:05:22.000Z - 4 months ago

Liquidia rises 18.2%

Liquidia falls -6.5%

2026-01-09T15:05:42.000Z - 4 months ago

Liquidia falls -6.5%

Liquidia sees Q4 Yutrepia net product sales $90.1M

2026-01-09T11:41:59.000Z - 4 months ago

Liquidia sees Q4 Yutrepia net product sales $90.1M

Liquidia Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 8:00 AM EST - 6 months ago

Liquidia Transcript: Jefferies London Healthcare Conference 2025

Liquidia Transcript: UBS Global Healthcare Conference 2025

Nov 10, 2025, 4:15 PM EST - 6 months ago

Liquidia Transcript: UBS Global Healthcare Conference 2025

Liquidia Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 6 months ago

Liquidia Earnings Call Transcript: Q3 2025

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

Nov 3, 2025, 8:00 AM EST - 6 months ago

Liquidia Corporation to Present at Upcoming Healthcare Investment Conferences

Liquidia Transcript: R&D Day 2025

Oct 28, 2025, 3:00 PM EDT - 7 months ago

Liquidia Transcript: R&D Day 2025

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 27, 2025, 8:30 AM EDT - 7 months ago

Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

Oct 7, 2025, 6:30 AM EDT - 7 months ago

Liquidia Corporation to Host R&D Day in New York City on October 28, 2025

Liquidia Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 3:45 PM EDT - 8 months ago

Liquidia Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

Aug 27, 2025, 8:30 AM EDT - 9 months ago

Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference

Liquidia Earnings Call Transcript: Q2 2025

Aug 12, 2025, 8:30 AM EDT - 9 months ago

Liquidia Earnings Call Transcript: Q2 2025

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 12, 2025, 6:30 AM EDT - 9 months ago

Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

Jun 23, 2025, 4:34 PM EDT - 11 months ago

Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA™

Liquidia Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 11:05 AM EDT - 1 year ago

Liquidia Transcript: Jefferies Global Healthcare Conference 2025

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

Jun 2, 2025, 6:30 AM EDT - 1 year ago

Liquidia Schedules First Commercial Shipment of YUTREPIA™ (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

May 28, 2025, 8:00 AM EDT - 1 year ago

Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference

Liquidia Transcript: Status Update

May 27, 2025, 8:30 AM EDT - 1 year ago

Liquidia Transcript: Status Update

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

May 23, 2025, 2:28 PM EDT - 1 year ago

U.S. FDA Approves Liquidia's YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Liquidia Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 4:40 PM EDT - 1 year ago

Liquidia Transcript: BofA Securities 2025 Healthcare Conference

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

May 12, 2025, 6:00 AM EDT - 1 year ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

Liquidia Earnings Call Transcript: Q1 2025

May 8, 2025, 8:30 AM EDT - 1 year ago

Liquidia Earnings Call Transcript: Q1 2025

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 6:30 AM EDT - 1 year ago

Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

May 2, 2025, 5:28 PM EDT - 1 year ago

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025

Liquidia Transcript: 24th Annual Needham Virtual Healthcare Conference

Apr 9, 2025, 8:45 AM EDT - 1 year ago

Liquidia Transcript: 24th Annual Needham Virtual Healthcare Conference

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 10:33 AM EDT - 1 year ago

UPDATE – Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 1, 2025, 8:00 AM EDT - 1 year ago

Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Mar 28, 2025, 9:30 AM EDT - 1 year ago

Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder

Liquidia Earnings Call Transcript: Q4 2024

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Liquidia Earnings Call Transcript: Q4 2024

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 19, 2025, 6:30 AM EDT - 1 year ago

Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Mar 12, 2025, 8:00 AM EDT - 1 year ago

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Liquidia Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 15, 2025, 12:45 PM EST - 1 year ago

Liquidia Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Liquidia Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 3:00 PM EST - 1 year ago

Liquidia Transcript: Stifel 2024 Healthcare Conference

Liquidia Earnings Call Transcript: Q3 2024

Nov 13, 2024, 8:30 AM EST - 1 year ago

Liquidia Earnings Call Transcript: Q3 2024

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 13, 2024, 6:30 AM EST - 1 year ago

Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent

Oct 7, 2024, 10:00 AM EDT - 1 year ago

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Oct 2, 2024, 6:00 AM EDT - 1 year ago

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting

Liquidia Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 1:30 PM EDT - 1 year ago

Liquidia Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

Sep 16, 2024, 9:41 AM EDT - 1 year ago

Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million

KeelinTime
KeelinTime May. 13 at 10:40 AM
$LQDA
0 · Reply
BDE_Worldwide
BDE_Worldwide May. 13 at 3:58 AM
$LQDA lol, been battlin’ shorts since 2021.. Know what you own. Buyout in 2026. Signed, sealed and delivered. 💎 🖐️
0 · Reply
BullRun4
BullRun4 May. 13 at 1:17 AM
$LQDA 👏🏻👏🏻👏🏻👏🏻⤵️⤵️⤵️⤵️😜😎💰
0 · Reply
KeelinTime
KeelinTime May. 13 at 12:33 AM
$LQDA
0 · Reply
JFais
JFais May. 12 at 10:45 PM
$LQDA (L) From today's trades
0 · Reply
IFeelLucky812
IFeelLucky812 May. 12 at 10:12 PM
$LQDA this story ends in an M&A story. I’ve been saying it for 5 years. PBM knows what they own and want top dollar. I wish I never trimmed my position, but still happy with what I hold from the $3 range. I remember fighting all the MNKD holders, I wonder what they are thinking!
0 · Reply
stevemano
stevemano May. 12 at 9:22 PM
$LQDA ridiculously overpriced!
1 · Reply
stevemano
stevemano May. 12 at 9:19 PM
$LQDA overvalued. Pump. N dump
0 · Reply
Quantumup
Quantumup May. 12 at 8:54 PM
BofA last night⬆️ $LQDA's PT to $64 (was $44), plus⬆️Yutrepia's peak sales estimates +40% to $1.7B while reiterating at Buy in its 1Q26 EPS wrap. $UTHR - MKND $INSM Here's what BofA had to say in its note to investors: https://x.com/Quantumup1/status/2054303381431505331?s=20
0 · Reply
truehealthvalue
truehealthvalue May. 12 at 7:56 PM
$LQDA @stevemano are you still live?
1 · Reply
Affizle
Affizle May. 12 at 7:50 PM
$MNKD Stevemano after getting his $LQDA short margin call from his broker LOLZ!
0 · Reply
Gambaa
Gambaa May. 12 at 7:31 PM
$LQDA Absolute monster lets print $60 this week
0 · Reply
monoksop
monoksop May. 12 at 6:36 PM
$LQDA Aged beautifully
0 · Reply
msgu1021
msgu1021 May. 12 at 4:01 PM
$LQDA Wow! this call resiliency. Solid fundamental. Remember earning call?... Roger (CEO) says that LQDA growing organically. They are funding growth from operation. Not borrowing the money...
1 · Reply
JFais
JFais May. 12 at 3:55 PM
$LQDA - intentionally keep my peak sales estimates overly conservative (avoid drinking the kool-aid) However, currently seeing wide range from analysts ($1.4B to potentially topping $3B) Even the midrange for Yutrepia represents just 2.1x EV of $4.7B (room to double from here)
1 · Reply
grampslol
grampslol May. 12 at 3:37 PM
$LQDA poor delusional cultist $MNKD pumper @stevemano ...smh...denying the reality of epic failure pennyland Afizzle dpi while trying to tease the winning lqda dpi...sad, in a funny way
1 · Reply
kiwitc2000
kiwitc2000 May. 12 at 3:37 PM
$COCO Still moving higher strong. Also $LQDA. Is staples and health finally getting some traction?
0 · Reply
jacksk
jacksk May. 12 at 3:05 PM
$LQDA is this worth buying if the growth falls off after 2027?
2 · Reply
Hamboning0
Hamboning0 May. 12 at 2:41 PM
$LQDA
2 · Reply
JFais
JFais May. 12 at 1:45 PM
Cheers my friend- I save most of my position updates for within ROTY Biotech Community (not fair to members if share elsewhere) Think SA still doing a sale there https://tinyurl.com/25v7j22r Regardless,2-week free trial should be enough to kick the tires & copy what you find useful $LQDA $HROW $RIGL
0 · Reply
Gambaa
Gambaa May. 12 at 1:06 PM
$LQDA $70PT too low!
0 · Reply
stevemano
stevemano May. 12 at 1:05 PM
$LQDA your numbers are erroneous and false
1 · Reply